RxDoctor Payments Data

Danil Makarov

Urology · New York, NYNPI 1730226366

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $703 of the $1,041 with a category attached, or 67.6%. 9 manufacturers reported payments, led by Sanofi at 55.0% of the total. Reporting peaked in 2019 at $706 and has fallen 97.4% since, to $18 in 2025. That places this record below the midpoint for urology clinicians in NY, where the typical reported total is $2,467.

$1,041in general payments, 2019–2025

Across 11 payments — averaging $94.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$573
  • Bayer$150
  • KARL Storz Endoscopy-america$133
  • AbbVie$51
  • Procept Biorobotics Corporation$39
  • Myriad Genetic Laboratories, Inc.$28
  • plus $68 from 3 others
$20,420in research payments, 2019–2025

Across 1 payment — averaging $20,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$20K

What the payments were for

  • Travel & lodging$32031%
  • Food & beverage$70368%
  • Other$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,041 in reported general payments places this provider in the 35th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024
$33,699
Medicare patients
137
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron67$41,273
Tamsulosin Hcl436$8,033
Estradiol23$3,015
Finasteride213$2,353
Tolterodine Tartrate ErTolterodine Tartrate18$1,734
Alfuzosin Hcl ErAlfuzosin Hcl62$1,319
Oxybutynin Chloride23$648
Dutasteride31$626
Solifenacin Succinate13$597
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$333

Paid to pharmacies, not to this prescriber.

Other urology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →